• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Amedisys Inc (NQ: AMED )

    97.56 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Aug 23, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 97.56
    Bid (Size) 71.00 (1)
    Ask (Size) 100.90 (2)
    Prev. Close 97.56
    Today's Range 97.56 - 97.56
    52wk Range 89.55 - 98.95
    Shares Outstanding 32,631,959
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Contessa Selected by Centers for Medicare & Medicaid Services to Test Medicare Dementia Care Model
    Guiding an Improved Dementia Experience (GUIDE) Model Aims to Increase Care Coordination, Support for Caregivers 
    From Amedisys, Inc.
    Via GlobeNewswire
    AMED Stock Earnings: Amedisys Beats EPS, Beats Revenue for Q2 2024
    AMED stock results show that Amedisys beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
    Via InvestorPlace

    Performance

    YTD
    +2.73%
    +2.73%
    1 Month
    -0.70%
    -0.70%
    3 Month
    +2.05%
    +2.05%
    6 Month
    +3.58%
    +3.58%
    1 Year
    +4.02%
    +4.02%

    More News

    Read More
    AMED Stock Earnings: Amedisys Beats EPS, Beats Revenue for Q1 2024
    Via InvestorPlace
    Dividend Growth Stars: 7 Stocks With 10-Year Double-Digit Rate Hikes
    Via InvestorPlace
    Is NASDAQ:AMED suited for quality investing?
    Via Chartmill
    What 11 Analyst Ratings Have To Say About Amedisys
    Via Benzinga
    Analyst Ratings for Amedisys
    Via Benzinga
    3 Stocks To Turn $1,000 Into $10,000 in 10 Years
    Via InvestorPlace
    3 Stocks Profiting from America’s Long-Term Care Crisis
    Via InvestorPlace
    Cantor Fitzgerald Maintains Neutral Rating for Amedisys: Here's What You Need To Know
    Via Benzinga
    The 3 Best Stock Picks for This Week
    Via InvestorPlace
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: EchoStar Corporation (Nasdaq - SATS), Sovos Brands, Inc. (Nasdaq - SOVO), Reata Pharmaceuticals, Inc. (Nasdaq - RETA), Amedisys, Inc. (Nasdaq – AMED)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    Expert Ratings for Amedisys
    Via Benzinga
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Reata Pharmaceuticals, Inc. (Nasdaq – RETA), Talaris Therapeutics, Inc. (Nasdaq – TALS), Inpixon® (Nasdaq – INPX), Amedisys, Inc. (Nasdaq – AMED)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: American Equity Investment Life Holding Company (NYSE – AEL), Amedisys, Inc. (Nasdaq – AMED), Sigilon Therapeutics, Inc (Nasdaq – SGTX)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: American Equity Investment Life Holding Company (NYSE – AEL), Amedisys, Inc. (Nasdaq – AMED), Sigilon Therapeutics, Inc (Nasdaq – SGTX)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    Is UnitedHealth Group Stock a Buy Now?
    Via The Motley Fool
    SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Amedisys, Inc. (Nasdaq – AMED)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    Benzinga's Top Ratings Upgrades, Downgrades For July 6, 2023
    Via Benzinga
    Meta Platforms To Rally Around 14%? Here Are 10 Other Analyst Forecasts For Thursday
    Via Benzinga
    Benzinga's Top Ratings Upgrades, Downgrades For June 28, 2023
    Via Benzinga
    AMED Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Amedisys, Inc. Is Fair to Shareholders
    From Halper Sadeh LLC
    Via Business Wire
    Benzinga's Top Ratings Upgrades, Downgrades For June 7, 2023
    Via Benzinga
    Benzinga's Top Ratings Upgrades, Downgrades For June 6, 2023
    Via Benzinga
    Optum's Decision To Target Amedisys Is Intriguing, Says Analyst
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.